Shares of Depomed had spiked as much as 13 percent before the trading halt. » Read More
Two-thirds of Americans want an independent body to oversee prescription drug pricing.
Intra-Cellular Therapies shares plunge 68 percent after study results on a schizophrenia drug trial. CNBC's Seema Mody reports.
Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid.
CNBC's Meg Tirrell reports the latest on Gilead. Geoff Porges, Leerink Partners managing director and senior biotech analyst, weighs in.
Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late-stage study.
Shares of Kite Pharma climbed 9 percent Tuesday after receiving positive clinical trial results for a non-Hodgkin's lymphoma treatment.
Bill George, CNBC Contributor and former Medtronic CEO, discusses Mylan CEO Heather Bresch's testimony to Congress over EpiPen pricing.
CNBC's Jim Cramer explains why he is watching pharmaceutical names.
"We view LLY as a compelling new products story with multiple assets on market or due to launch over the next couple of years," Goldman Sachs says.
Every pharma CEO needs to step up and say these outrageous drug-price hikes are not OK, says former Medtronic CEO Bill George. e.
Jim Cramer spoke with the CEO of GW Pharmaceuticals following breakthrough results for its drug Epidiolex.
Rep. Elijah Cummings (D-Maryland) reacts to the new report saying pre-tax profits on Mylan's EpiPen were 60 percent higher than CEO Heather Bresch told Congress last week. CNBC's Meg Tirrell reports.
Discussing Mylan's EpiPen profit calculations and how to view the stock, with Ronny Gal, Sanford Bernstein Senior Analyst.
CNBC's Meg Tirrell reports the latest on Mylan's EpiPen profit numbers as told to Congress.
CNBC's Meg Tirrell reports the latest developments in Mylan's EpiPen pricing scandal. The "FMHR" traders and Jim Cramer weigh in.
Mylan said on Monday the auto-injector EpiPen pretax profits were higher than it told Congress, according to Dow Jones.
Get the best of CNBC in your inbox